CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 55 enrolled
Drug / intervention
Blood draw +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05912400
NCT05912400N/ACompleted
CompareCT.gov

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1

University of Arkansas·observational·Posted Jun 22, 2023·Updated May 8, 2025

In Brief

An observational study evaluating Blood draw and FACIT-F and Pain Scales for Neurofibromatosis 1. Completed, enrolled 55 participants across 1 site.

Detailed Summary

Neurofibromatosis type 1 is a common genetic disease with a broad spectrum of clinical manifestations in multiple organs of the body. This project will study the (dys)function of mitochondria in patients with neurofibromatosis through multiple collections of blood samples from patients and people not afflicted by neurofibromatosis (control group). This study will evaluate how the function of mitochondria changes with time and if medications and supplements can influence the function of the mitochondria. Patients will also answer questions regarding symptoms like fatigue and pain.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNeurofibromatosis 1
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedJun 22, 2023
Enrollment StartJul 26, 2023
Primary CompletionAug 23, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.0 years ago

Interventions

Blood drawother

• An additional 10 mL of blood will then be drawn for mitochondrial testing purposes.

FACIT-F and Pain Scalesother

• Questionnaires regarding pain and fatigue will be provided for the subject to review and answer.